Cerebral infarction following intracranial hemorrhage in pediatric Moyamoya disease - A case report and brief review of literature.

Moyamoya disease is a clinical entity characterized by progressive cerebrovascular occlusion with spontaneous development of a collateral vascular network called Moyamoya vessels. This disease mainly manifests as cerebral ischemia. Intracranial bleeding is another major presentation of patients with Moyamoya disease. We report here a 12-year-old male child who presented with severe headache, vomiting and meningismus. Initial neuroimaging study with noncontrast computed tomography scan revealed fresh intraventricular hemorrhage in right-sided lateral ventricle. Magnetic resonance imaging with angiography of brain was done 5 days later when the child developed right-sided hemiparesis, and the diagnosis of Moyamoya disease was confirmed along with lacunar infarction of right posterior peri and paraventricular area and in the left paraventricular area and centrum semiovale. Simultaneous presence of cerebral infarction along with intraventricular hemorrhage in adult with bleeding-type Moyamoya disease is reported in literature, but it is a rare entity in a child.

Effectiveness of beta blockers in primary prophylaxis of variceal bleeding in children with portal hypertension.

AIM: The primary aim of our study was to assess the effectiveness of beta blockers in non bleeding portal hypertensive children. The secondary objective was to evaluate whether the newer generation beta blockers were superior compared to conventional ones. METHODS: Conventional propranolol and newer generation carvedilol were administered to 31 subjects each, after stratifying them into nearly equal subgroups according to etiology (sinusoidal or presinusoidal). RESULTS: At the end of 2 years study period, 3 children (4.83%) had breakthrough bleeding. A decrease, increase and no alteration in grade of oesophageal varices was seen in 40, 9 and 13 cases respectively. Of the 9 children with associated gastroeosophageal varices (GOV), the severity of lesions was reduced in 8 of them. Both the drugs had efficacious outcome in sinusoidal as well as presinusoidal cases, having a significant coefficient of correlation (r > 0.5) with time. Carvedilol was more effective than propranolol statistically (p = 0.035 and p = 0.034 respectively), only at 4 and 5 month follow-up period. CONCLUSION: Beta blockers are effective in preventing variceal bleed in children with portal hypertension. Long-term efficacy of carvedilol and propranolol was similar.

Effect of carbamazepine therapy on vitamin D and parathormone in epileptic children.

Evidence suggests that carbamazepine affects bone metabolism by altering vitamin D status. We prospectively compared 25-hydroxyvitamin D, parathormone, calcium, phosphorus, and alkaline phosphatase levels at initiation and 6 months of carbamazepine therapy in children, and correlated them with carbamazepine levels. We included 47 children newly diagnosed with partial epilepsy, initiated on carbamazepine therapy. Of these, 32 were studied for 6 months. Children were managed according to standard protocol. Various parameters were measured at initiation and at 6 months. Carbamazepine levels were estimated after 6 months. Mean age was 6.72 ± 2.22 years S.D. Mean 25-hydroxyvitamin D was 14.45 ± 9.77 ng/mL S.D. and 11.31 ± 9.15 ng/mL S.D. at baseline and 6 months (P = 0.023), respectively (21.7% decline). Mean parathormone increased from 34.24 ± 21.38 pg/mL S.D. to 45.01 ± 24.46 pg/mL S.D. (P = 0.001). Change in vitamin D correlated negatively with change in parathormone (r = -0.404, P = 0.022). Serum alkaline phosphatase increased from 283.50 ± 100.10 IU/L S.D. to 364.25 ± 126.98 IU/L S.D. (P < 0.001). Changes in vitamin D and parathormone did not correlate significantly with carbamazepine level. Carbamazepine therapy decreased levels of vitamin D. Hence vitamin D monitoring and supplementation may help prevent alterations in bone metabolism.